After our July interview with CEO Kelsey Ramsden about the company’s Ibogaine synthesis, August brought more exciting announcements for Mind Cure Health Inc (CNSX: MCUR) (OTCMKTS: MCURF). Ramsden joins us once more to talk about the beta release of iSTRYM things to look forward to for Mind Cure in Q4 and beyond.
Here’s some highlights from the interview.
Beta release of iSTRYM proof that Mind Cure delivers to investors
The beta version of iSTRYM has been released, and full commercial distribution is expected in Q1 of 2022.
Read More
